WARPTECHNEWS · LAB
HomeAIBusinessTechArchive
WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

  • Home
  • Archivio
  • Editor's Brief
  • Cerca
  • Il tuo account
  • Newsletter tech/AI

Informazioni legali

  • Privacy Policy
  • Termini di servizio
  • Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Home
Storia in 2 fonti

Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

Raccontata damorningstar.comendpoints.news

Confronto fonti

2 prospettive sulla stessa storia
AI · summaries
morningstar.comStai leggendo4 g fa

Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following…

Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

originale
endpoints.news4 g fa

How one biotech is using 'digital twins' to study a muscle disease therapy

Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI

Leggi questa versione → originale

Timeline cronologica

  1. venerdì 26 giugno 2026·morningstar.com

    Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

    Epicrispr Reports First Clinical Evidence of Increased Lean Muscle Volume in Patients with FSHD Following Treatment with EPI-321

  2. venerdì 26 giugno 2026·endpoints.news

    How one biotech is using 'digital twins' to study a muscle disease therapy

    Epicrispr reports early cut data showing lean muscle gains on its FSHD epigenetic editing therapy EPI-321, using AI